Home FUNDING

Skyhawk Therapeutics Completes New Investment Round

Skyhawk Therapeutics, Inc. today announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors.

This brings total equity funding plus partnership capital in the Company to over $600 million thus far, with potential future milestones of over $20 billion plus ongoing royalties.

“This investment round strengthens Skyhawk’s capacity to advance our internal pipeline of drug candidates deep into the clinic,” said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. “We are delighted that investors support our novel platform, a strong foundation from which to advance a series of our internal drugs for patients, even as we expand our work making drug candidates for our pharma collaborators.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version